MyoPax, a Berlin-based developer of cell and gene therapies, raised a Pre-Seed funding round from B# Plus. The new funding will advance its manufacturing processes and support its first clinical trials.
Round Type
Pre-Seed
GermanyManufacturingBiotechnologyHealth CareTherapeuticsInvestors
Description
MyoPax, based in Berlin, Germany, has secured Pre-Seed funding to enhance its pharmaceutical manufacturing and prepare for clinical trials. The company specializes in cell and gene therapies aimed at treating muscle diseases. This investment will help expand its therapeutic platform. B# Plus, focusing on female founders, led the investment.
Who to call at MyoPax, and when
A new round usually means MyoPax is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day MyoPax raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at MyoPax, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at MyoPax. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment MyoPax raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
MyoPax raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.